BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38564927)

  • 1. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
    Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
    Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
    Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
    Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
    Lauritsen J; Sauvé N; Tryakin A; Jiang DM; Huddart R; Heng DYC; Terbuch A; Winquist E; Chovanec M; Hentrich M; Fankhauser CD; Shamash J; Del Muro XG; Vaughn D; Heidenreich A; Sternberg CN; Sweeney C; Necchi A; Bokemeyer C; Bandak M; Jandari A; Collette L; Gillessen S; Beyer J; Daugaard G
    Br J Cancer; 2023 Nov; 129(11):1759-1765. PubMed ID: 37777577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
    Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
    Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
    Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
    JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
    J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
    Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
    Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
    Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
    Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
    Beyer J; Collette L; Sauvé N; Daugaard G; Feldman DR; Tandstad T; Tryakin A; Stahl O; Gonzalez-Billalabeitia E; De Giorgi U; Culine S; de Wit R; Hansen AR; Bebek M; Terbuch A; Albany C; Hentrich M; Gietema JA; Negaard H; Huddart RA; Lorch A; Cafferty FH; Heng DYC; Sweeney CJ; Winquist E; Chovanec M; Fankhauser C; Stark D; Grimison P; Necchi A; Tran B; Heidenreich A; Shamash J; Sternberg CN; Vaughn DJ; Duran I; Bokemeyer C; Patrikidou A; Cathomas R; Assele S; Gillessen S;
    J Clin Oncol; 2021 May; 39(14):1553-1562. PubMed ID: 33729863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
    Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
    World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre.
    Beg A; Kumar R; Sahay A; Janu A; Joshi A; Noronha V; Prabhash K; Karimundackal G; Jiwnani S; Agarwal JP; Pramesh CS
    Ann Diagn Pathol; 2021 Aug; 53():151763. PubMed ID: 34111707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
    Funt SA; Patil S; Feldman DR; Motzer RJ; Bajorin DF; Sheinfeld J; Tickoo SK; Reuter VE; Bosl GJ
    J Clin Oncol; 2019 Sep; 37(26):2329-2337. PubMed ID: 31233353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).
    Germà-Lluch JR; Garcia del Muro X; Maroto P; Paz-Ares L; Arranz JA; Gumà J; Alba E; Sastre J; Aparicio J; Fernández A; Barnadas A; Terrassa J; Sáenz A; Almenar D; López-Brea M; Climent MA; Sánchez MA; Lasso de la Vega R; Berenguer G; Pérez X;
    Eur Urol; 2002 Dec; 42(6):553-62; discussion 562-3. PubMed ID: 12477650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
    Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
    Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators.
    Deville JL; Gravis G; Salem N; Savoie PH; Esterni B; Walz J; Thomas P; Goncalves A; Viens P; Bladou F
    Eur J Cancer Care (Engl); 2010 Nov; 19(6):827-32. PubMed ID: 19708949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
    Hentrich M; Debole J; Jurinovic V; Gerl A
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival of poor-risk non-seminomatous germ cell tumor patients: real-world data from a single institute in Japan.
    Tanuma K; Kawai K; Nitta S; Shiga M; Kawahara T; Negoro H; Onozawa M; Inoue T; Nishiyama H; Miyazaki J
    Jpn J Clin Oncol; 2023 Jan; 53(1):74-79. PubMed ID: 36151048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.